[go: up one dir, main page]

ES2031467T3 - Formulaciones acuosas de esteroides apropiadas para administracion por via nasal. - Google Patents

Formulaciones acuosas de esteroides apropiadas para administracion por via nasal.

Info

Publication number
ES2031467T3
ES2031467T3 ES198787107416T ES87107416T ES2031467T3 ES 2031467 T3 ES2031467 T3 ES 2031467T3 ES 198787107416 T ES198787107416 T ES 198787107416T ES 87107416 T ES87107416 T ES 87107416T ES 2031467 T3 ES2031467 T3 ES 2031467T3
Authority
ES
Spain
Prior art keywords
approximately
weight
administration via
aqueous formulations
via nasal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787107416T
Other languages
English (en)
Inventor
Eric Joel Benjamin
Shabbir Tyabji Anik
Ya-Yin Tracy Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex Pharmaceuticals International Ltd
Original Assignee
Syntex Pharmaceuticals International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Pharmaceuticals International Ltd filed Critical Syntex Pharmaceuticals International Ltd
Application granted granted Critical
Publication of ES2031467T3 publication Critical patent/ES2031467T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

UNA FORMULACION ESTEROIDE, ANTIINFLAMATORIA, ACUOSA, NO COMPUNGIVA, ADECUADA PARA LA ADMINISTRACION INTRANASAL COMPRENDE: UN ESTEROIDE ANTIINFLAMATORIO EN UNA CANTIDAD COMPRENDIDA ENTRE APROXIMADAMENTE 0,01% Y APROXIMADAMENTE 0,05% (PESO/VOLUMEN); PROPILENCLICOL EN UNA CANTIDAD COMPRENDIDA ENTRE APROXIMADAMENTE 2% Y APROXIMADAMENTE 10% (PESO/VOLUMEN); PEG400 EN UNA CANTIDAD COMPRENDIDA ENTRE APROXIMADAMENTE 10% Y APROXIMADAMENTE 25% (PESO/VOLUMEN); POLISORBATO 20 EN UNA CANTIDAD COMPRENDIDA ENTRE APROXIMADAMENTE 1% Y APROXIMADAMENTE 4% (PESO/VOLUMEN); UNA CANTIDAD EFICAZ DE UN CONSERVANTE; UNA CANTIDAD EFICAZ DE UN ESTABILIZADOR; UNA CANTIDAD EFICAZ DE UN ANTIOXIDANTE; AGUA; Y UNA CANTIDAD DE TAMPOM PH SUFICIENTE PARA AJUSTAR EL PH DE LA SOLUCION RESULTANTE A UN VALOR ENTRE APROXIMADAMENTE 3,5 Y APROXIMADAMENTE 7.
ES198787107416T 1986-05-22 1987-05-21 Formulaciones acuosas de esteroides apropiadas para administracion por via nasal. Expired - Lifetime ES2031467T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/866,171 US4782047A (en) 1986-05-22 1986-05-22 Aqueous steroid formulations for nasal administration

Publications (1)

Publication Number Publication Date
ES2031467T3 true ES2031467T3 (es) 1992-12-16

Family

ID=25347059

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787107416T Expired - Lifetime ES2031467T3 (es) 1986-05-22 1987-05-21 Formulaciones acuosas de esteroides apropiadas para administracion por via nasal.

Country Status (19)

Country Link
US (1) US4782047A (es)
EP (1) EP0246652B1 (es)
JP (1) JP2521291B2 (es)
KR (1) KR950008308B1 (es)
AT (1) ATE65183T1 (es)
AU (1) AU609718B2 (es)
CA (1) CA1288048C (es)
DE (1) DE3771389D1 (es)
DK (1) DK175238B1 (es)
ES (1) ES2031467T3 (es)
FI (1) FI88459C (es)
GR (1) GR3002317T3 (es)
HK (1) HK39094A (es)
IE (1) IE60259B1 (es)
IL (1) IL82615A (es)
IT (1) IT1205667B (es)
NO (1) NO173365C (es)
NZ (1) NZ220394A (es)
ZA (1) ZA873663B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983595A (en) * 1986-05-22 1991-01-08 Syntex (U.S.A.) Inc. Aqueous steroid formulations for nasal administration
JPH0311016A (ja) * 1989-06-09 1991-01-18 Tokyo Tanabe Co Ltd ピリド［１，２―ａ］ピリミジン誘導体の水性製剤
GB9103824D0 (en) * 1991-02-23 1991-04-10 Fisons Ag Formulation
US5338732A (en) * 1991-06-18 1994-08-16 Bristol-Myers Squibb Company Megestrol acetate formulation
AU681452B2 (en) * 1993-10-21 1997-08-28 Hisamitsu Pharmaceutical Co., Inc. Pernasal composition and pernasal preparation containing thesame
US5762917A (en) * 1994-09-27 1998-06-09 Virotex Corporation Method and composition for cleansing wounds with minimal cytotoxicity for minimal scarring
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US8466134B1 (en) 1998-06-26 2013-06-18 Athena Neurosciences, Inc. Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
GB9918559D0 (en) * 1999-08-07 1999-10-06 Glaxo Wellcome Kk Novel pharmaceutical formulation
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US6948492B2 (en) 2000-08-15 2005-09-27 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
CA2493764C (en) 2002-08-01 2011-05-24 Aesgen, Inc. Improved treatment of cancer with glutamine
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US7404489B1 (en) 2003-03-04 2008-07-29 Qol Medical, Llc Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
JP5238779B2 (ja) * 2003-04-25 2013-07-17 ロート製薬株式会社 点鼻剤
JP4632687B2 (ja) * 2003-04-25 2011-02-16 ロート製薬株式会社 点鼻剤
CA2550811C (en) * 2003-12-24 2012-05-01 Jane Hirsh Temperature-stable formulations, and methods of development thereof
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
US20060045850A1 (en) * 2004-08-30 2006-03-02 Qpharma, Llc Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
BRPI0517891A (pt) 2004-11-24 2008-10-21 Medpointe Healthcare Inc composições compreendendo azelastina e métodos de uso das mesmas
JP2009504767A (ja) 2005-08-17 2009-02-05 フレミング・アンド・カンパニー・ファーマシューティカルズ ビタミンｂ１２鼻用スプレーおよび使用方法
KR100767976B1 (ko) 2006-08-25 2007-10-18 한국유나이티드제약 주식회사 비내 건조증에 효과적인 약제학적 조성물
CN101678112B (zh) 2007-01-19 2016-08-31 哈南亚有限公司 用于递送治疗剂的方法和组合物
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
JP2011001317A (ja) * 2009-06-19 2011-01-06 Fumakilla Ltd 鼻用洗浄剤
CA2905587A1 (en) 2013-03-15 2014-09-18 Medicis Pharmaceutical Corporation Topical compositions of flunisolide and methods of treatment
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
JP6097787B2 (ja) * 2015-06-09 2017-03-15 パル ファーマシューティカル， インコーポレーテッド 鼻内送達用シアノコバラミン低粘度水性製剤
EA036233B1 (ru) 2015-07-16 2020-10-16 Мариномед Биотек Аг Способ улучшения растворимости в воде лекарственных средств, нерастворимых или слаборастворимых в воде
US11510859B2 (en) 2015-07-16 2022-11-29 Marinomed Biotech Ag Method for improving aqueous solubility of water-insoluble or slightly water-soluble drugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2989437A (en) * 1955-06-08 1961-06-20 Upjohn Co Anti-inflammatory and anti-bacterial decongestant nasal spray compositions
MX3864E (es) * 1975-05-27 1981-08-26 Syntex Corp Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
US4444762A (en) * 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US4344940A (en) * 1981-11-30 1982-08-17 E. R. Squibb & Sons, Inc. Steroid formulation containing dipotassium EDTA
US4603131A (en) * 1982-04-26 1986-07-29 Bernstein Joel E Method and composition for treating and preventing irritation of the mucous membranes of the nose

Also Published As

Publication number Publication date
IT1205667B (it) 1989-03-31
DK258687A (da) 1987-11-23
CA1288048C (en) 1991-08-27
IT8720621A0 (it) 1987-05-21
GR3002317T3 (en) 1992-12-30
AU7327387A (en) 1987-11-26
JP2521291B2 (ja) 1996-08-07
ZA873663B (en) 1988-12-28
FI88459C (fi) 1993-05-25
EP0246652A2 (en) 1987-11-25
KR870010862A (ko) 1987-12-18
KR950008308B1 (ko) 1995-07-27
IL82615A0 (en) 1987-11-30
NZ220394A (en) 1990-04-26
NO173365C (no) 1993-12-08
DK175238B1 (da) 2004-07-19
FI872231A0 (fi) 1987-05-21
NO872127D0 (no) 1987-05-21
JPS62283927A (ja) 1987-12-09
EP0246652B1 (en) 1991-07-17
DE3771389D1 (de) 1991-08-22
NO173365B (no) 1993-08-30
US4782047A (en) 1988-11-01
NO872127L (no) 1987-11-23
AU609718B2 (en) 1991-05-09
IE60259B1 (en) 1994-06-29
IL82615A (en) 1991-11-21
DK258687D0 (da) 1987-05-21
FI872231L (fi) 1987-11-23
EP0246652A3 (en) 1988-02-03
HK39094A (en) 1994-04-29
FI88459B (fi) 1993-02-15
ATE65183T1 (de) 1991-08-15
IE871335L (en) 1987-11-22

Similar Documents

Publication Publication Date Title
ES2031467T3 (es) Formulaciones acuosas de esteroides apropiadas para administracion por via nasal.
KR890700036A (ko) 비내 투여용 제제 및 그 제조방법
DK0971705T3 (da) Lægemiddelformuleringer til hormonerstatningsterapi til lokal påföring på huden
DZ1067A1 (fr) Nouvelles préparations pharmaceutiques à emission prolongée.
DE3381396D1 (de) Formulierung nicht irritierender ophthalmischer waesseriger zusammensetzungen fuer okular-therapeutische mittel.
ES2038632T3 (es) Una preparacion para curar heridas y su procedimiento de elaboracion.
ES2152259T3 (es) Productos de cereales listos para comer enriquecidos con beta-caroteno.
ES2171525T3 (es) Composiciones farmaceuticas para uso topico conteniendo acido (s)-2-(4-isobutilfenil)propionico.
DE3767114D1 (de) Stabilisierte arzneimittel.
FI883338A0 (fi) Vattenloesningar av doxorubicinhydroklorid.
US3526698A (en) Stabilization of levo-3-(3,4-dihydroxyphenyl)-2-methylalanine with sodium bisulfite and sorbitol
ZA934573B (en) Preparation for topical use
ES2059756T3 (es) Composiciones farmaceuticas que contienen primicina.
DE68901852D1 (de) Primycin-loesungen.
ES2043093T3 (es) Composicion para uso cosmetico o farmaceutico.
SE8303012D0 (sv) Farmaceutisk komposition
IT1262960B (it) Composizioni farmaceutiche somministrabili per via intranasale contenenti calcitonina quale principio attivo.
JPS55136228A (en) Novel antiallergic agent
AU1257888A (en) Stable, injectable solutions of vinca dimer salts
ECSP961648A (es) Formulacion transdermica

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 246652

Country of ref document: ES